Exhibit 10.53
|
|
|
|
|
Note:
|
|
Redacted
portions have been marked with [*]. The redacted portions are
subject to a request for confidential treatment that has been filed
with the Securities and Exchange Commission.
|
AMENDMENT NO. 2
TO
AMENDMENT NO. 6
TO THE
ENBREL
®
SUPPLY
AGREEMENT
This Amendment No. 2 to
Amendment No. 6 (“Amendment No. 6.2”) is made
this 26th day of August, 2008 (the “Amendment No. 6.2
Effective Date”) by and among IMMUNEX CORPORATION, a
corporation of the State of Washington, having its principal place
of business at One Amgen Center Drive, Thousand Oaks, California,
91320, U.S.A., together with its Affiliates
(“Immunex”), WYETH (formerly known as American
Home Products Corporation), a corporation of the State of Delaware
having its corporate headquarters at Five Giralda Farms, Madison,
New Jersey 07940, U.S.A. and acting through its Wyeth
Pharmaceuticals Division (“Wyeth”), and BOEHRINGER
INGELHEIM PHARMA GMBH & CO. KG , a German corporation
having a place of business at Birkendorfer Straße 65, 88397
Biberach an der Riss, Federal Republic of Germany
(“BIP”), and amends the Enbrel Supply Agreement
effective as of November 5, 1998, by and among Immunex, Wyeth,
and BIP, and as amended (the “Agreement”).
WHEREAS, Immunex,
Wyeth and BIP have entered into a certain Agreement for BIP’s
supply of Enbrel ® (etanercept) to Immunex and
Wyeth; and
WHEREAS, the Parties originally
intended to transfer the manufacturing process to a Second
Generation Pro
